Temperature Maintenance of Biopharmaceuticals USA 2013 - Boston, MA, 5 - 6 June

Peptide Specialty Laboratories (PSL) - Peptide Synthesis and Antibody Production

Clinical Trial Supply West Coast 2013 - 29 - 30 May, San Francisco, US

Biovian - Contract Manufacturing Of Biopharmaceuticals

Xbrane Bioscience - E. coli Protein Expression Systems

Proven Autoclave Design a Long Runner
Top-loading laboratory autoclaves are the longest serving stalwarts of the Priorclave steam steriliser range, a 100l model being the first produced and to leave the company's factory in 1988 when it started trading, and through dedicated service and support many of these early models can still be found in use today, performing routine sterilisation processes some 25 years later.

Bachem Adds 11 New Research Products to Online Catalogue
Bachem is continuously expanding and updating its extensive range of biologically active peptides, amino acid derivatives, biochemicals and immunology products.

Meet Biovian at BioTrinity 2013 - European Biopartnering and Investment Conference - 14-16 May 2013, Newbury, UK
Meet Biovian at BioTrinity 2013 - European Biopartnering and Investment Conference - 14-16 May 2013, Newbury, UK.

New Mammalian cGMP Cell Banking Facility Commissioned by Fujifilm Diosynth Biotechnologies
Fujifilm Diosynth Biotechnologies has announced that it has commissioned on time its new mammalian cGMP Cell Banking Facility (CBF) at its Billingham, UK site.

Tissue Solutions to Exhibit at 2013 BIO International Convention, Booth 4438, Apr 22 - 25, 2013, in Chicago IL, US
Tissue Solution invites pharmaceutical and biotech companies to visit booth 4438 at this year's BIO International Convention 2013. We will be showcasing our unique tissue acquisition service and demonstrating the significant benefits of using high quality human tissue.

Use of the Fios Genomics Analysis Approach for Determining Immunity Pathways
This study determined which immunological pathways are responsible for clearance of parasitic infections in people affected by river...

Melusine Venom Libraries: Designed to Discover Tomorrow's Drugs
Melusine Venom Libraries are high-quality venoms prepared and pre-fractionated on an automated platform and dispensed in micro-plates ready for high throughput screening (HTS) in targeted...

Rubber Oligomers Now Available at Toxikon
Toxikon Europe, a leading lab in providing extractables and leachables services for the pharmaceutical industry, has developed a procedure to obtain and analyse pure rubber oligomers from...

Cocrystals in the Pharmaceutical and Fine Chemicals Industry: From an Option to an Opportunity
In the drug discovery and development arena it is well known that the choice of the right solid form can have a dramatic influence on the successful development of an active...

Oligosaccharides in Drug Discovery
Glycobiology offers enormous untapped potential in the discovery of new therapeutics derived from saccharides or other molecules which target the biosynthesis and function of...

Straight to the source – targeted pain relief
Diamyd Medical, a Swedish biopharmaceutical company, has taken huge steps towards revolutionising the treatment of intractable pain. Through their Nerve Targeting Drug Delivery System (NTDDS) the developers hope to bring new relief to cancer, diabetes and chronic pain sufferers. Dr Nicola Davies reports.

A more permeable pathway – next generation transdermal drug delivery
Researchers at MIT have discovered a way to make skin more permeable by using ultrasound waves, opening up the possibility of transdermal patches delivering larger molecular drugs. Heidi Vella discovers what this new research and other next generation transdermal patches could mean for the future of conventional drug delivery.

Breaking barriers – the potential of subcutaneous drug delivery
Cancer rates are rising sharply just as healthcare providers are being asked to implement enormous efficiency savings, making innovation crucial to the future of cancer care. Elly Earls met Halozyme's Kurt Gustafson and Roche Products' Julian Cole, to find out how a revolutionary new subcutaneous drug delivery platform called ENHANZE™ could be part of the solution.

Imperial marches into Africa - building a drug supply chain
Africa's dire need for pharmaceuticals is well-documented, but so are logistical problems involved in transporting sensitive drugs across long distances in the continent's tropical climate and harsh terrain. Dr Nicola Davies spoke to Johannesburg-based Imperial Holdings, who recently made a bold move to improve their logistics chain by acquiring the pharmaceutical and consumer healthcare supply chain of South Africa's RTT Group.

Tumour-targeting ADCs: delivering the anti-cancer warhead
Antibody-drug conjugates combine the efficacy of cytotoxic drugs and the tumour-specific targeting of antibodies to maximise anti-cancer potency and minimise side effects. Chris Lo talks to experts in the field of ADC development to discover the potential of this burgeoning treatment type, and the challenges involved in getting it right.

Simbrinza (brinzolamide/brimonidine tartrate) for the Reduction of Elevated Intraocular Pressure
Simbrinza (brinzolamide/brimonidine tartrate) is a carbonic anhydrase inhibitor developed by Alcon, a division of Novartis.

Oxytrol (oxybutynin) for the Treatment of Overactive Bladder (OAB) in Women
Oxytrol (oxybutynin) is a transdermal patch indicated for the treatment of overactive bladder in women who have symptoms of urge urinary incontinence, urgency and frequency.

Zytiga (abiraterone acetate) - Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Developed by Coughar Biotechnology, abiraterone acetate (CB7630) was discovered by the UK Institute for Cancer Research.

Korlym (Mifepristone) for Treatment of Endogenous Cushing’s Syndrome
Korlym (mifepristone) is a glucocorticoid receptor blocker indicated for the control of high blood sugar levels in adult patients suffering from endogenous Cushing's syndrome.

Elelyso (Taliglucerase Alfa) for Treating Gaucher Disease
Elelyso (taliglucerase alfa) is an intravenous drug indicated for the treatment of type one Gaucher disease. The drug was jointly developed by Protalix BioTherapeutics and Pfizer.